Compare Stocks: IMDX, NVCT, VSTM, and TECX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMDX Oncocyte	$4.77 -1.2%	$5.21	$2.33 ▼ $8.51	$155.96M	1.79	161,398 shs	73,259 shs
NVCT Nuvectis Pharma	$18.88 -0.4%	$17.56	$5.55 ▼ $29.27	$617.42M	-0.26	245,945 shs	137,149 shs
TECX Tectonic Therapeutic	$32.71 +5.6%	$31.31	$14.39 ▼ $39.53	$605.64M	3.28	169,279 shs	139,360 shs
VSTM Verastem	$6.79 +0.7%	$4.91	$3.43 ▼ $11.24	$610.40M	0.26	2.22 million shs	2.30 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMDX Oncocyte	-1.24%	-5.17%	-6.10%	-4.22%	+476,999,900.00%
NVCT Nuvectis Pharma	-0.37%	-12.59%	+2.89%	+73.21%	+214.67%
TECX Tectonic Therapeutic	+5.58%	+17.16%	-4.83%	+16.99%	+46.62%
VSTM Verastem	+0.74%	+19.33%	+22.78%	+46.65%	+0.74%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IMDX Oncocyte	$4.77 -1.2%	$5.21	$2.33 ▼ $8.51	$155.96M	1.79	161,398 shs	73,259 shs
NVCT Nuvectis Pharma	$18.88 -0.4%	$17.56	$5.55 ▼ $29.27	$617.42M	-0.26	245,945 shs	137,149 shs
TECX Tectonic Therapeutic	$32.71 +5.6%	$31.31	$14.39 ▼ $39.53	$605.64M	3.28	169,279 shs	139,360 shs
VSTM Verastem	$6.79 +0.7%	$4.91	$3.43 ▼ $11.24	$610.40M	0.26	2.22 million shs	2.30 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IMDX Oncocyte	-1.24%	-5.17%	-6.10%	-4.22%	+476,999,900.00%
NVCT Nuvectis Pharma	-0.37%	-12.59%	+2.89%	+73.21%	+214.67%
TECX Tectonic Therapeutic	+5.58%	+17.16%	-4.83%	+16.99%	+46.62%
VSTM Verastem	+0.74%	+19.33%	+22.78%	+46.65%	+0.74%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IMDX Oncocyte	2.00	Hold	$12.00	151.57% Upside
NVCT Nuvectis Pharma	2.33	Hold	$35.00	85.38% Upside
TECX Tectonic Therapeutic	2.75	Moderate Buy	$77.80	137.85% Upside
VSTM Verastem	2.91	Moderate Buy	$13.83	103.73% Upside

Current Analyst Ratings Breakdown

Latest IMDX, NVCT, VSTM, and TECX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	VSTM Verastem	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Outperform	$14.00 ➝ $13.00
8/7/2026	VSTM Verastem	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$14.00 ➝ $12.00
8/7/2026	TECX Tectonic Therapeutic	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$101.00 ➝ $93.00
8/5/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/20/2026	TECX Tectonic Therapeutic	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/17/2026	TECX Tectonic Therapeutic	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	VSTM Verastem	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Outperform	$15.00 ➝ $14.00
7/6/2026	NVCT Nuvectis Pharma	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$33.00
7/6/2026	NVCT Nuvectis Pharma	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $33.00
7/2/2026	VSTM Verastem	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00
6/24/2026	IMDX Oncocyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IMDX Oncocyte	$4.05M	38.03	N/A	N/A	($1.10) per share	-4.34
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.72 per share	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$13.43 per share	N/A
VSTM Verastem	$30.91M	19.89	N/A	N/A	$0.74 per share	9.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IMDX Oncocyte	-$50.22M	-$1.48	N/A	N/A	N/A	-2,454.64%	N/A	-96.96%	N/A
NVCT Nuvectis Pharma	-$26.44M	-$1.31	N/A	N/A	N/A	N/A	-184.25%	-105.24%	N/A
TECX Tectonic Therapeutic	-$74.15M	-$4.57	N/A	N/A	N/A	N/A	-34.35%	-32.80%	N/A
VSTM Verastem	-$209.47M	-$2.66	N/A	N/A	N/A	-231.59%	-492.59%	-93.39%	N/A

Latest IMDX, NVCT, VSTM, and TECX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	IMDX Oncocyte	N/A	-$0.23	N/A	-$0.31	N/A	$0.24 million
8/6/2026	Q2 2026	TECX Tectonic Therapeutic	-$1.35	-$1.18	+$0.17	-$1.18	N/A	N/A
8/6/2026	Q2 2026	VSTM Verastem	-$0.4305	-$0.35	+$0.0805	-$0.35	$22.88 million	$40.08 million
8/4/2026	Q2 2026	NVCT Nuvectis Pharma	-$0.2620	-$0.30	-$0.0380	-$0.30	N/A	N/A
5/13/2026	Q1 2026	IMDX Oncocyte	N/A	-$0.28	N/A	-$0.12	N/A	$0.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IMDX Oncocyte	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IMDX Oncocyte	N/A	2.54	2.51
NVCT Nuvectis Pharma	N/A	1.68	1.68
TECX Tectonic Therapeutic	N/A	18.51	18.51
VSTM Verastem	0.89	3.04	3.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IMDX Oncocyte	55.35%
NVCT Nuvectis Pharma	96.77%
TECX Tectonic Therapeutic	62.63%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
IMDX Oncocyte	2.21%
NVCT Nuvectis Pharma	28.55%
TECX Tectonic Therapeutic	39.80%
VSTM Verastem	1.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IMDX Oncocyte	120	32.29 million	31.58 million	N/A
NVCT Nuvectis Pharma	8	32.58 million	23.28 million	Not Optionable
TECX Tectonic Therapeutic	120	19.55 million	11.77 million	N/A
VSTM Verastem	50	90.56 million	88.81 million	Optionable

IMDX, NVCT, VSTM, and TECX Headlines

Recent News About These Companies

Verastem (NASDAQ:VSTM) Shares Gap Up on Earnings Beat

August 9 at 1:21 AM | americanbankingnews.com

Verastem (NASDAQ:VSTM) Posts Earnings Results, Beats Estimates By $0.08 EPS

August 7, 2026 | marketbeat.com

Verastem Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Verastem (NASDAQ:VSTM) Shares Gap Up Following Better-Than-Expected Earnings

August 7, 2026 | marketbeat.com

Verastem Restructures Oberland Financing to Support Commercialization

August 7, 2026 | tipranks.com

Verastem, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 7, 2026 | seekingalpha.com

Verastem Reiterated as Buy on Strong AVMAPKI FAKZYNJA Momentum, VS-7375 Progress; $18 Price Target Maintained

August 7, 2026 | tipranks.com

Verastem: Q2 Earnings Snapshot

August 6, 2026 | chron.com

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

August 6, 2026 | finance.yahoo.com

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 2, 2026 | americanbankingnews.com

Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Moderate Buy" by Brokerages

August 2, 2026 | marketbeat.com

Verastem’s TARGET-D 202 Trial Puts Fresh Focus on KRAS G12D Lung Cancer

July 30, 2026 | tipranks.com

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic ...

July 30, 2026 | finance.yahoo.com

Verastem Oncology (NASDAQ:VSTM) Draws Fresh Market Focus

July 30, 2026 | kalkinemedia.comK

Verastem (VSTM) to Post Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Verastem, Inc. $VSTM Shares Bought by Exome Asset Management LLC

July 28, 2026 | marketbeat.com

Wall Street Zen Upgrades Verastem (NASDAQ:VSTM) to "Hold"

July 25, 2026 | marketbeat.com

Verastem (NASDAQ:VSTM) Stock Price Up 6% - Still a Buy?

July 23, 2026 | marketbeat.com

Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026

July 23, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMDX, NVCT, VSTM, and TECX Company Descriptions

Oncocyte NASDAQ:IMDX

$4.77 -0.06 (-1.24%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$4.15 -0.62 (-13.00%)

As of 04:00 AM Eastern

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Nuvectis Pharma NASDAQ:NVCT

$18.88 -0.07 (-0.37%)

As of 08/10/2026 04:00 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Tectonic Therapeutic NASDAQ:TECX

$32.71 +1.73 (+5.58%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$32.80 +0.09 (+0.26%)

As of 07:03 AM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

Verastem NASDAQ:VSTM

$6.79 +0.05 (+0.74%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$6.65 -0.14 (-2.02%)

As of 08:15 AM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMDX, NVCT, VSTM, and TECX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMDX, NVCT, VSTM, and TECX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMDX, NVCT, VSTM, and TECX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMDX, NVCT, VSTM, and TECX Company Descriptions

Oncocyte NASDAQ:IMDX

Nuvectis Pharma NASDAQ:NVCT

Tectonic Therapeutic NASDAQ:TECX

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMDX, NVCT, VSTM, and TECX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMDX, NVCT, VSTM, and TECX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMDX, NVCT, VSTM, and TECX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMDX, NVCT, VSTM, and TECX Company Descriptions

Oncocyte NASDAQ:IMDX

Nuvectis Pharma NASDAQ:NVCT

Tectonic Therapeutic NASDAQ:TECX

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools